ProFunds Biotechnology UltraSector Fund Investor Class BIPIX:NASDAQ

Net Asset Value$63.45Previous Close - 12/13/2019
1-Day Change-0.22(0.35%)
YTD Change+11.54(22.23%)

Growth of $10,000 Since Fund Inception

View portfolioPortfolio as of 07/31/2019

Top 5 SectorsTop 5 Holdings
Health Technology67.81%
Amgen Inc ORD11.42%
Other6.50%
Abbvie Inc ORD9.88%
Health Services2.83%
Gilead Sciences Inc ORD8.36%
Commercial Services1.25%
Celgene Corp ORD6.50%
  
Biogen Inc ORD4.63%
Concentration of Top 578.39% Concentration of Top 540.79% 

Fund Profile

Fund Strategy

The Fund seeks daily investment results, before fees and expenses, that correspond to one and one-half times (1.5x) the daily performance of the Dow Jones U.S. Biotechnology Index for a single day. The Index seeks to measure the performance of certain companies in the biotechnology sector of the U.S. equity market.

Fund Category Sector Equity
Inception Date 06/19/2000
Manager Neches/Dave
Fund Classification Equity Leverage Funds
Managed Since 2013
Other Managed Funds   UYG  ROM  BIB  INPIX  URE

Lipper Leader Scorecard as of 11/30/2019

RatingTotal
Return
Consistent
Return
PreservationTax
Efficiency
Expense*
Overall Rating(# of funds in category)
193

187

12,203

192

43
3 Year Rating(# of funds in category)
193

190

12,203

192

43
5 Year Rating(# of funds in category)
169

167

10,417

169

41
10 Year Rating(# of funds in category)
121

121

7,071

121

39

Fund Highlights

Total Expense Ratio1.52%
Average Market Capitallization$56.6 B
Net Asset ValueN/A
Total Net Assets$195.5 M
Sales ExpensesNo Load Fund
Minimum Initial Investment$15000
Minimum IRA Investment$15000
AvailabilityOpen to New Investors
Current Yield0.00%
Dividend Ex-DateN/A

Risk Analysis

Beta vs. S&P 5001.73
R-Squared vs. S&P 5000.54
Standard Deviation28.39%
Sharpe Ratio0.45
Portfolio TurnoverN/A